Single Agent Abraxane as Second Line Therapy in Bladder Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by Sunnybrook Health Sciences Centre.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Celgene Corporation
Information provided by:
Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT00683059
First received: May 21, 2008
Last updated: July 19, 2011
Last verified: July 2011
  Purpose

The purpose of this study is to determine what effects the drug Abraxane has on bladder cancer.


Condition Intervention Phase
Transitional Cell Carcinoma
Drug: Paclitaxel
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Institutional Phase II Study of Single Agent Abraxane as Second Line Therapy in Patients With Advanced Transitional Cell Carcinoma of the Urothelium

Resource links provided by NLM:


Further study details as provided by Sunnybrook Health Sciences Centre:

Primary Outcome Measures:
  • Response rate [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • safety [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • overall survival [ Time Frame: 1-2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 48
Study Start Date: March 2008
Estimated Study Completion Date: September 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Paclitaxel
    total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
    Other Name: Abraxane
Detailed Description:

For those patients with advanced bladder cancer who have progressed on a platinum based regimen, no widely accepted standard second line therapy currently exists. Taxanes including paclitaxel have exhibited clinical activity in this disease and are sometimes given off study. However, toxicities including neurotoxicity and hypersensitivity reactions often limit the use of paclitaxel. ABRAXANE may allow delivery of a greater dose of paclitaxel to those with bladder cancer with an easier method of administration and with less toxicity.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histological or cytological diagnosis of urothelial carcinoma. Mixed histologies are permitted as long as transitional cell carcinoma is the major component (i.e. >50% of the pathologic specimen). Pure or predominant squamous cell carcinomas are not permitted.
  • Patients with transitional cell carcinomas of the renal pelvis and ureter are permitted.
  • Patients must have metastatic or locally advanced unresectable disease.
  • Patients must have received one and only one prior chemotherapeutic regimen which included a platinum (at least one cycle) for metastatic/recurrent disease. Neoadjuvant or adjuvant chemotherapy will be considered to have been first line if the patient progressed within 12 months of the last dose.
  • Neoadjuvant/adjuvant chemotherapy (with or without a taxane) is permitted if registration is greater than 12 months since the last dose (patients must then have received one platinum containing regimen in the metastatic setting)
  • ECOG performance status <= 2.
  • Estimated life expectancy of >12 weeks.
  • Patients must have measurable disease according to RECIST criteria.
  • If female of childbearing potential, pregnancy test is negative within 72 hours priors to first dose of study drug.
  • If fertile, patient agrees to use an effective method of contraception to avoid pregnancy for the duration of the study.
  • Adequate organ function; Absolute neutrophil count >1.5 x 109/L. Platelet count >100 x109/L. Hemoglobin >90 g/L. Total bilirubin <1.5x upper limit of normal. Transaminases <3x upper limit of normal (<5x if liver metastasis are present) Calculated creatinine clearance >40 ml/min (Cockcroft & Gault formula)
  • Able to give informed consent.

Exclusion Criteria:

  • Prior taxane therapy for metastatic disease (or > 12 months since a taxane-containing neoadjuvant or adjuvant chemotherapy).
  • Pre-existing peripheral neuropathy >1 by NCI-CTC criteria.
  • Pregnant or lactating females.
  • Uncontrolled brain or leptomeningeal involvement (treated brain metastasis permitted if both known lesions and medications e.g. steroids for that indication are stable).
  • History of serious or concurrent illness that might be aggravated by study treatment.
  • History of class II-IV congestive heart failure.
  • Other malignancies except adequately controlled basal cell carcinoma of the skin or carcinoma in situ of the cervix or incidental prostate cancer (T1a, Gleason <7 PSA <10ng/ml) or any other tumor within 5 years prior to enrollment.
  • Other investigational therapy or radiation therapy within 30 days before registration.
  • Patients not willing to employ adequate contraception for the duration of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00683059

Contacts
Contact: Yoo-Joung Ko, MD 416-480-4928 yoo-joung.ko@sunnybrook.ca

Locations
Canada, Ontario
Juravinski Cancer Centre Recruiting
Hamilton, Ontario, Canada, L8V 5C2
Contact: Som Mukherjee, MD    905-387-9711 ext 64605    som.mukherjee@hrcc.on.ca   
Principal Investigator: Som Mukherjee, MD         
London Regional Cancer Program Not yet recruiting
London, Ontario, Canada, N6A 4L6
Contact: Eric Winquist, MD    519-685-8640    Eric.Winquist@lhsc.on.ca   
Principal Investigator: Eric Winquist, MD         
Ottawa Regional Cancer Centre Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Christina Canil, MD    613 737-7700    ccanil@Ottawahospital.on.ca   
Principal Investigator: Christina Canil, MD         
Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Yoo Joung Ko, MD    416-480-4928    yoo-joung.ko@sunnybrook.ca   
Principal Investigator: Yoo-Joung Ko, MD         
Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Srikala Sridhar, MD    416-946-2249    srikala.sridhar@uhn.on.ca   
Principal Investigator: Srikala Sridhar, MD         
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Celgene Corporation
Investigators
Principal Investigator: Yoo-Joung Ko, MD Sunnybrook Health Sciences Centre
  More Information

No publications provided by Sunnybrook Health Sciences Centre

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. Yoo-Joung Ko, Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT00683059     History of Changes
Other Study ID Numbers: ABX207-GU07CA
Study First Received: May 21, 2008
Last Updated: July 19, 2011
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 21, 2014